Treating BCG-induced disease in children

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 1, 2013, Pages

  Cuello García, Carlos A ^a   Pérez Gaxiola, Giordano ^b   Jiménez Gutiérrez, Carlos ^c  

^a ESCUELA DE MEDICINA Y CIENCIAS DE LA SALUD   (Mexico)

^b Hospital Pediátrico de Sinaloa   (Mexico)

^c INSTITUTO NACIONAL DE PERINATOLOGÍA   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CIPROFLOXACIN; ERYTHROMYCIN; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; OFLOXACIN; RIFAMPICIN; IMMUNOLOGICAL ADJUVANT; TUBERCULOSTATIC AGENT;

ABSCESS; BACILLUS CALMETTE GUERIN VACCINE INDUCED DISEASE; BCG VACCINATION; DISEASE COURSE; DRUG INDUCED DISEASE; FINE NEEDLE ASPIRATION BIOPSY; FOLLOW UP; HUMAN; INTENTION TO TREAT ANALYSIS; LYMPHADENITIS; LYMPHADENITIS ABSCESS; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SAMPLE SIZE; SYSTEMATIC REVIEW; CHILD; INFANT; META ANALYSIS; METHODOLOGY; MICROBIOLOGY; MYCOBACTERIUM BOVIS; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL (TOPIC); SUCTION;

ABSCESS; ADJUVANTS, IMMUNOLOGIC; ANTIBIOTICS, ANTITUBERCULAR; BCG VACCINE; CHILD; CHILD, PRESCHOOL; ERYTHROMYCIN; HUMANS; INFANT; ISONIAZID; LYMPHADENITIS; MYCOBACTERIUM BOVIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RIFAMPIN; SUCTION;

MLCS; MLOWN;

EID: 84874798059     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD008300.pub2     Document Type: Review

References (58)

1. Banani SA, Alborzi A. Needle aspiration for suppurative post-BCG adenitis. Archives of Disease in Childhood 1994;71(5):446-7.
2. Caglayan S, Yegin O, Kayran K, Timocin N, Kasirga E, Gun M. Is medical therapy effective for regional lymphadenitis following BCG vaccination?. American Journal of Diseases of Children 1987;141(11):1213-4.
3. Close GC, Nasiiro R. Management of BCG adenitis in infancy. Journal of Tropical Pediatrics 1985;31(5):286.
4. Kuyucu N, Kuyucu S, Ocal B, Tezic T. Comparison of oral erythromycin, local administration of streptomycin and placebo therapy for nonsuppurative Bacillus Calmette-Guerin lymphadenitis. The Pediatric Infectious Disease Journal 1998;17(6):524-5.
5. Noah PK, Pande D, Johnson B, Ashley D. Evaluation of oral erythromycin and local isoniazid instillation therapy in infants with Bacillus Calmette-Guerin lymphadenitis and abscesses. The Pediatric Infectious Disease Journal 1993;12(2):136-9.
6. Amato Neto V, de Oliveira e Silva YK, Finger H, Bianchi A, do Amaral JP, Cardozo BS, et al.Analysis of the adverse effects occurring after the administration of BCG by oral route in 5, 579 healthy children [Análise das manifestações colaterais decorrentes da administração da vacina BCG, por via oral, a 5, 579 crianças sadias]. Revista Paulista De Medicina 1973;82(3):135-8.
7. Au FC, Webber B, Rosenberg SA. Pulmonary granulomas induced by BCG. Cancer 1978;41(6):2209-14.
8. Balkan E, Sapan N, Unal M, Dogruyol H. Treatment of the suppurative BCG lymphadenitis [Süpüre BCG Lenfadenit Tedavisi]. Pediatrik Cerrahi Dergisi 1992;6:29-32.
9. Bhandari B, Khurana R, Mandowara SL. Management of post-BCG lymphadenitis. Indian Journal of Pediatrics 1980;47(388):367-70.
10. Caglayan S, Arikan A, Yaprak I, Aksoz K, Kansoy S. Management of suppuration in regional lymph nodes secondary to BCG vaccination. Acta Paediatrica Japonica 1991;33(6):699-702.
11. Cerdá de Palou E, de Santy HP. Lymphadenitis as a complication following vaccination with Bacillus Calmette-Guérin (BCG). Nederlands Tijdschrift voor Geneeskunde 2003;147(12):569-72.
12. Chavganc J, Hanák R, ten Dam HG. Epidemiological significance of the local reaction to direct BCG vaccination as assessed from a study in Mongolia. Bulletin of the World Health Organization 1969;41(1):45-62.
13. De Britto RL, Ramanathan VD, Gupte MD. Regional lymphadenitis following antileprosy vaccine BCG with killed Mycobacterium leprae. International journal of leprosy and other mycobacterial diseases 1997;65(1):12-9.
14. Easton PA, Hershfield ES. Lymphadenitis as a late complication of BCG vaccination. Tubercle 1984;65(3):205-8.
15. Ferreira AA, Bunn-Moreno MM, Sant'Anna CC, Ferreira MF. BCG vaccination in low birth weight newborns: analysis of lymphocyte proliferation, IL-2 generation and intradermal reaction to PPD. Tubercle and Lung Disease 1996;77(5):476-81.
16. Goraya JS, Virdi VS. Treatment of Calmette-Guérin bacillus adenitis: a metaanalysis. The Pediatric Infectious Disease Journal 2001;20(6):632-4.
17. Guld J, Magnus K, Tolderlund K, Biering-Sorensen K, Edwards PQ. Suppurative lymphadenitis following intradermal B.C.G. vaccination of the newborn; a preliminary report. British Medical Journal 1955;2(4947):1048-54.
18. Gür E, Arvas A. Dose of Calmette-Guérin bacillus vaccination in infants. The Pediatric Infectious Disease Journal 2002;21(4):359-60.
19. Hanley SP, Gumb J, Macfarlane JT. Comparison of erythromycin and isoniazid in treatment of adverse reactions to BCG vaccination. British Medical Journal (Clinical research ed.) 1985;290(6473):970.
20. Hengster P, Sölder B, Fille M, Menardi G. Surgical treatment of bacillus Calmette Guérin lymphadenitis. World Journal of Surgery 1997;21(5):520-3.
21. Kendrick MA, Comstock GW. BCG vaccination and the subsequent development of cancer in humans. Journal of the National Cancer Institute 1981;66(3):431-7.
22. Koivisto M, Brander E, Hakosalo J, Wasz-Höckert O. Comparative study of 3 BCG vaccines [Kolmen BCG-rokotteen vertaileva tutkimus]. Duodecim 1974;90(24):1717-22.
23. Lachmann D, Howanietz L. Clinical aspect and therapy of BCG-lymphadenitis (author's transl). Pädiatrie und Pädologie 1976;11(1):283-6.
24. Mitinskaia LA, Lukhimenko NV, Kamaeva VF. BCG vaccination and increasing the effectiveness of treatment of post-vaccination complications by the use of rifampicin and dimexide. Problemy Tuberkuleza 1994;5:4-7.
25. Nazir Z, Qazi SH. Bacillus Calmette-Guerin (BCG) lymphadenitis-changing trends and management. Journal of Ayub Medical College, Abbottabad: JAMC 2005;17(4):16-8.
26. Oğuz F, Müjgan S, Alper G, Alev F, Neyzi O. Treatment of Bacillus Calmette-Guérin-associated lymphadenitis. The Pediatric Infectious Disease Journal 1992;11(10):887-8.
27. Rabie H, Violari A, Duong T, Madhi SA, Josipovic D, Innes S, et al.Early antiretroviral treatment reduces risk of bacille Calmette-Guérin immune reconstitution adenitis. The International Journal of Tuberculosis and Lung Disease: the official journal of the International Union against Tuberculosis and Lung Disease 2011;15(9):1194-200.
28. Samileh N, Ahmad S, Farzaneh A, Shahnaz R, Lida F, Mohammad N. Immunity status in children with Bacille Calmette-Guerin adenitis. A prospective study in Tehran, Iran. Saudi Medical Journal 2006;27(11):1719-24.
29. Teulieres L, Diouf MA, Chaud P, Saint-Cyr A, Saliou P. Comparative trial of administration of half (0.05 mg) and quarter (0.025 mg) dose of intradermal Pasteur BCG on 291 infants from birth to 1 year in French Guyana. Vaccine 1991;9(7):521-4.
30. Thayyil-Sudhan S, Kumar A, Singh M, Paul VK, Deorari AK. Safety and effectiveness of BCG vaccination in preterm babies. Archives of Disease in Childhood. Fetal and neonatal edition 1999;81(1):F64-6.
31. Yuan Y, Wu M, Dai X, Ni Z, Su G. Study on different treatment methods of tuberculous lymphadenitis caused by BCG vaccination. Journal of Clinical Internal Medicine 2001;18(3):226.
32. Bolger T, O'Connell M, Menon A, Butler K. Complications associated with the bacille Calmette-Guérin vaccination in Ireland. Archives of Disease in Childhood 2006;91(7):594-7.
33. Bonnlander H, Rossignol AM. Complications of BCG vaccinations in rural Haiti. American Journal of Public Health 1993;83(4):583-5.
34. Deeks SL, Clark M, Scheifele DW. Serious adverse events associated with Bacille Calmette-Guérin vaccine in Canada. Pediatric Infectious Disease Journal 2005;24(6):538-41.
35. Fine P, Carneiro I, Milstein JB, Clements CJ. BCG immunization policies. Issues relating to the use of BCG in immunisation programmes. Geneva: World Health Organization (WHO/V&B/99.23) 1999.
36. Fitzgerald JM. Management of adverse reactions to Bacille Calmette-Guérin vaccine. Clinical Infectious Diseases 2000;31(Suppl 3):S75-6.
37. French MAH. Immune reconstitution inflammatory syndrome: immune restoration disease 20 years on. The Medical Journal of Australia 2012;196(5):318-21.
38. Goraya JS, Virdi VS. Bacille Calmette-Guérin lymphadenitis. Postgraduate Medical Journal 2002;78(920):327-9.
39. Hatherill M. Prospects for elimination of childhood tuberculosis: the role of new vaccines. Archives of Disease in Childhood 2011;96(9):851-6.
40. Hesselberg I. Drug resistance in the Swedish/Norwegian BCG strain. Bulletin of the World Health Organization 1972;46(4):503-7.
41. Hesseling AC, Schaaf HS, Victor T, Beyers N, Marais BJ, Cotton MF, et al.Resistant Mycobacterium bovis Bacillus Calmette-Guérin disease: implications for management of Bacillus Calmette-Guérin Disease in human immunodeficiency virus-infected children. Pediatric Infectious Disease Journal 2004;23(5):476-9.
42. Hesseling AC, Rabie H, Marais BJ, Manders M, Lips M, Schaaf HS, et al.Bacille Calmette-Guérin Vaccine-Induced Disease in HIV-Infected and HIV-Uninfected Children. Clinical Infectious Diseases 2006;42(4):548-58.
43. Hesseling AC, Marais BJ, Gie RP, Schaaf HS, Fine PE, Godfrey-Faussett P, et al.The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children. Vaccine 2007;25(1):14-8.
44. Higgins JPT, Altman DG, Sterne JAC (editors). Assessing risk of bias in included studies. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org. 2011.
45. Karpelowsky JS, Alexander AG, Dix Peek S, Millar AJW, Rode H. Surgical complications of bacille Calmette-Guérin (BCG) infection in HIV-infected children: Time for a change in policy?. South African Medical Journal 2008;98(10):801-4.
46. Lotte A, Wasz-Hockert O, Poisson N, Dumitrescu N, Verron M, Couvet E. BCG complications: estimates of risks among vaccinated subjects and statistical analysis of their main characteristics. Advances in Tuberculosis Research 1984;21:107-93.
47. Lotte A, ten Dam HG, Henderson R. Second IUATLD study on complications induced by intradermal BCG vaccination. Bulletin of the International Union Against Tuberculosis and Lung Disease 1988;63(2):47-83.
48. Milstien JB, Gibson JJ. Quality control of BCG vaccine by WHO: a review of factors that may influence vaccine effectiveness and safety. Bulletin of the World Health Organization 1990;68(1):93-108.
49. Milstien JB. Immunological Basis for Immunization / Module 5: Tuberculosis. (WHO/EPI/GEN/93.15). Geneva: World Health Organization 1993.
50. Nuttall JJC, Eley BS. BCG Vaccination in HIV-Infected Children. Tuberculosis Research and Treatment 2011;2011:712736.
51. Nuttall JJ, Davies MA, Hussey GD, Eley BS. Bacillus Calmette-Guérin (BCG) vaccine-induced complications in children treated with highly active antiretroviral therapy. International Journal of Infectious Diseases 2008;12(6):e99-105.
52. O'Brien KL, Ruff AJ, Louis MA, Desormeaux J, Joseph DJ, McBrien M, et al.Bacillus Calmette-Guérin complications in children born to HIV-1-infected women with a review of the literature. Pediatrics 1995;95(3):414-8.
53. Rabie H, Violari A, Madhi S, Gibb D, Steyn J, van Niekerk R, et al.Complications of BCG Vaccination in HIV-infected and uninfected Children: CHER Study. Proceedings of the 15th Conference on Retroviruses and Opportunistic Infections. Boston: Foundation for Retrovirology and Human Health, 2008.
54. Ritz N, Tebruegge M, Connell TG, Sievers A, Robins-Browne R, Curtis N. Susceptibility of Mycobacterium bovis BCG vaccine strains to antituberculous antibiotics. Antimicrobial Agents and Chemotherapy 2009;53(1):316-8.
55. Sakula A. BCG: who were Calmette and Guérin?. Thorax 1983;38(11):806-12.
56. Sharma SK, Soneja M. HIV & immune reconstitution inflammatory syndrome (IRIS). The Indian Journal of Medical Research 2011;134(6):866-77.
57. Talbot EA, Perkins MD, Silva SF, Frothingham R. Disseminated bacille Calmette-Guérin disease after vaccination: case report and review. Clinical Infectious Diseases 1997;24(6):1139-46.
58. World Health Organization. Revised BCG vaccination guidelines for infants at risk for HIV infection. The Weekly Epidemiological Record 2007;82(21):193-6.